1-(thiazol-2-yl)ethyl acetate | 125653-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(thiazol-2-yl)ethyl acetate
• 英文别名: 2-(1-Acetoxyethyl)thiazole；1-(2-Thiazolyl)ethyl acetate；1-(1,3-thiazol-2-yl)ethyl acetate
• CAS: 125653-76-1
• 化学式: C₇H₉NO₂S
• 分子量: 171.22
• InChiKey: AKOYHCVTBWJWGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(thiazol-2-yl)ethyl acetate 生成 2-vinylthiazole
  参考文献：
  名称：

  电芳族反应性通过酯的热解。部分21σ +为噻唑值：高极化性的噻唑，和氢键上的反应性的效果Ñ含杂环

  摘要：

  在633.2至698.5 K之间测得了从1-芳基乙酸乙酯（气相色谱中芳基=噻唑-2-基，噻唑-4-基，噻唑-5-基或苯基）中乙酸的气相消除速率。在650K下的热解速率为：噻唑-2-基，0.271；和。噻唑-4-基，0.491; 和噻唑-5-基，1.104；和 再加上先前确定的反应ρ因子（在650 K时为–0.61），则得出相应的σ +值0.93、0.505和–0.07。通过π电子密度计算正确地预测了位置反应性顺序和相对于苯的反应性。与噻吩的反应性在热解和溶剂分解反应中都非常相似的相反，每个位置的反应性基本上小于相应的1-芳基-1-氯乙烷的溶剂化反应。因此，噻唑比噻吩具有更大的极化性，因此特别容易受到各个过渡态共振稳定化的需求，在热解中需求较少。噻唑2位和相应的噻吩α位反应性之间的差异（1。72 sigma单位）明显大于噻唑4位和噻吩β位置（0.885 sigma单位）的反应性之差。这反映出较高的2

  DOI：

  10.1039/p29860001265
• 作为产物：
  描述：

  2-乙基噻唑 在 nickel(IV) oxide 、 N-溴代丁二酰亚胺(NBS) 、 一水合肼 、 silver nitrate 作用下， 以 四氯化碳 、 乙醇 、 二氯甲烷 为溶剂， 反应 2.5h， 生成 1-(thiazol-2-yl)ethyl acetate
  参考文献：
  名称：

  1,2,3-triazolo[5,1-b]thiazoles; synthesis and properties

  摘要：

  The synthesis of 1,2,3-triazolo[5,1-b]thiazole (15) and its 3-methyl- (16) and 3-phenyl- (17) derivatives is reported, together with their spectra, quaternisation, and ring opening reactions.

  DOI：

  10.1016/s0040-4020(01)87090-3

文献信息

• Method and composition for rejuvinating cells, tissues organs, hair and nails
  申请人：——

  公开号：US20020188015A1

  公开（公告）日：2002-12-12

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一个实施例中，本发明涉及包含药物组合物的化合物和组合物，其中药物组合物包含这些化合物，并且相关方法解耦蛋白质、脂质、核酸和其他生物材料以及它们的任意组合的糖介导偶联。在另一个实施例中，这些组合物和相关方法在体内具有实用性，用于减少生物体暴露于内部摄入、经皮应用或其他方式的化合物或组合物时，糖介导偶联过程的有害影响。在另一个实施例中，这些组合物和相关方法对器官、细胞和组织的离体处理以及头发、指甲和皮肤的外部处理具有用处，通过改变可变性和增加组织扩散系数来使它们恢复活力。在另一个实施例中，本发明涉及新颖的化合物和药物组合物。
• Palladium-catalyzed oxidative C–H/C–H cross-coupling of benzothiazoles with thiophenes and thiazoles
  作者：Xuxing Chen、Xiaojing Huang、Qian He、Yuyuan Xie、Chunhao Yang

  DOI：10.1039/c4cc00362d

  日期：——

  A concise palladium-catalyzed method for oxidative C–H/C–H cross-coupling between benzothiazoles and thiophenes/thiazoles has been developed. This CDC reaction is insensitive to air and moisture with high functional group tolerance.

  开发了一种简洁的钯催化方法，用于苯并噻唑与噻吩/噻唑之间的氧化C-H/C-H交叉偶联反应。这种CDC反应对空气和湿气不敏感，具有高度的官能团耐受性。
• Method and composition for rejuvenating cells, tissues organs, hair and nails
  申请人：——

  公开号：US06777557B2

  公开（公告）日：2004-08-17

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一种实施方式中，本发明涉及化合物和组合物，包括含有该化合物的药物组合物及相关方法，解除糖介导的蛋白质、脂质、核酸和其他生物材料及其任何组合的耦合。在另一种实施方式中，该组合物和相关方法在体内具有实用性，用于减少生物体暴露于该化合物或组合物内部时，糖介导的耦合过程的有害影响。该化合物或组合物可以通过口服、经皮应用或其他方式进行摄入。在另一种实施方式中，该组合物和相关方法适用于外体器官、细胞和组织的外体治疗，以及用于改变其可变形性和增加组织扩散系数的头发、指甲和皮肤的再生。在进一步的实施方式中，本发明涉及新型化合物和药物组合物。
• Method and composition for rejuvenating cells, tissues, organs, hair and nails
  申请人：——

  公开号：US07022721B1

  公开（公告）日：2006-04-04

  In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

  在一种实施例中，本发明涉及化合物和组合物，包括含有该化合物的制药组合物以及相关方法，该方法解除糖介导的蛋白质、脂质、核酸和其他生物材料的耦合，以及任何组合。在另一种实施例中，该组合物和相关方法在体内具有实用性，用于减少有机体暴露于该化合物或组合物内部时，糖介导的耦合过程的有害影响，通过摄入、经皮应用或其他方式。在另一种实施例中，该组合物和相关方法对于外部处理头发、指甲和皮肤，以改变可变性和增加组织扩散系数，使它们恢复活力，具有外体处理器官、细胞和组织的作用。在另一种实施例中，本发明涉及新型化合物和制药组合物。
• Substituted thioacetamides
  申请人：CEPHALON, INC.

  公开号：EP2186803A2

  公开（公告）日：2010-05-19

  The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.

  本发明涉及取代的硫代乙酰胺的化学组合物、其制备工艺以及组合物在治疗疾病中的用途。